AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Both lecanemab and donanemab are costly treatments that may ... The current longitudinal study was conducted at the Knight Alzheimer Disease Research Center (KnightADRC) at Washington University.

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab ...

and administered their first dose of donanemab in January of this year. More than 700,000 people in the UK currently suffer from Alzheimer's disease. Recent analysis by the Alzheimer's Society ...

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...